Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluconazole - powder for oral suspension - 10 milligram(s)/millilitre - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluconazole - powder for oral suspension - 40 milligram(s)/millilitre - triazole derivatives; fluconazole

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

biomed aust pty ltd - methadone hydrochloride, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: water for injections; colour - biodone forte is indicated for the detoxification and maintenance treatment of dependence on opioid drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 48 mg/ml - oral liquid, solution - excipient ingredients: benzoic acid; hydrochloric acid; purified water; potassium sorbate; allura red ac; glycerol; macrogol 1500; propylene glycol; saccharin sodium; sorbitol solution (70 per cent) (non-crystallising); flavour - for the relief of pain and fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 24 mg/ml - oral liquid, solution - excipient ingredients: glycerol; macrogol 1500; ponceau sx; saccharin sodium; propylene glycol; purified water; benzoic acid; potassium sorbate; flavour; maltitol solution - relief of pain and fever in children.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for suspension - voriconazole 40 mg/ml - voriconazole - voriconazole - treatment of : - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; purified water; propyl hydroxybenzoate; lactic acid - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; polysorbate 40; citric acid monohydrate; glycerol; purified water; carmellose sodium; ethanol; vanillin; carmoisine; sucrose; sunset yellow fcf; aluminium magnesium silicate; flavour - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 50 mg/ml;   - granules for oral suspension - 250 mg/5ml - active: clarithromycin 50 mg/ml   excipient: carbomer castor oil citric acid monohydrate hydrated silica hypromellose phthalate fruit mix flavour maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.